Incyte saw the highest growth of 1.52% in patent filings and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.58% and grants by 0.62%. GlobalData’s DataBook provides a comprehensive analysis of Incyte‘s patent filings and grants. Buy the databook here.
Incyte has been focused on protecting inventions in United States(US) with 32 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 31% filings and 29% grants. The United States(US), European Patent Office(EPO), Australia(AU), and Israel(IL) patent Office are among the top ten patent offices where Incyte is filings its patents. Among the top granted patent authorities, Incyte has 29% of its grants in United States(US), 11% in Australia(AU) and 7% in European Patent Office(EPO).
Roche and Johnson & Johnson could be the strongest competitors for Incyte
Patents related to rare diseases and climate change lead Incyte's portfolio
Incyte has the highest number of patents in rare diseases followed by, climate change and Covid-19. For rare diseases, nearly 64% of patents were filed and 78% of patents were granted in Q2 2024.
Lymphoma related patents lead Incyte portfolio followed by breast cancer, and lung cancer
Incyte has highest number of patents in lymphoma followed by breast cancer, lung cancer, pancreatic cancer, and leukemia. For lymphoma, nearly 1% of patents were filed and 1% of patents were granted in Q2 2024.
For comprehensive analysis of Incyte's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.